Author details

Full Name

Tari A King

Affiliation

ORCID

Career Start Year

1998

Papers

245

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36920410	Association of Surgery With Frailty Status in Older Women With Early-Stage Breast Cancer.		2023
36171529	Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis.	Ann Surg Oncol	2023
36222934	ASO Visual Abstract: Screening MRI Does Not Increase Cancer Detection or Result in Earlier Stage at Diagnosis in Patients with High-Risk Breast Lesions-A Propensity Score Analysis.	Ann Surg Oncol	2023
35941343	Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy.	Ann Surg Oncol	2023
36206024	Racial-ethnic variations in phyllodes tumors among a multicenter United States cohort.	Journal of Surgical Oncology	2023
36435614	Surgical Management of the Axilla for Breast Cancer.	Hematology/Oncology Clinics of North America	2023
37851196	Trends in Locoregional Therapy in Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer by Frailty and Life Expectancy.		2023
37670122	Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial.		2023
37596450	Great Debate: The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer.		2023
38071708	Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors.		2023
37966707	Opportunities for De-Escalation of Axillary Surgery in Patients with Ductal Carcinoma in Situ with Microinvasion.		2023
37626335	Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study.	BMC Prim Care	2023
37777685	Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.		2023
38047578	Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.		2023
36587173	Local Regional Recurrence Rates Are Low Following Neoadjuvant Endocrine Therapy: What Are the Remaining Barriers to its Widespread Adoption?		2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
36951169	Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.	Cancer	2023
37194964	Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.	J Am Coll Surg	2023
37192427	Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.	JCO Oncol Pract	2023
37126938	Uncertainties and controversies in axillary management of patients with breast cancer.	Cancer Treat Rev	2023
37436607	Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy.		2023
37433282	Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.	Cancer Cell	2023
37433103	Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.	J Clin Oncol	2023
37043210	Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.	JAMA Surg	2023
34949533	De-escalating axillary surgery in early-stage breast cancer.	Breast	2022
35771367	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.	Annals of Surgical Oncology	2022
35902504	ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.	Ann Surg Oncol	2022
35900704	Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.	Breast Cancer Research and Treatment	2022
35900648	Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.	Ann Surg Oncol	2022
35763229	Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.	Annals of Surgical Oncology	2022
35385998	Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer.	Annals of Surgical Oncology	2022
36096572	What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?		2022
35831521	ASO Visual Abstract: Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer.	Annals of Surgical Oncology	2022
35752703	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.	Breast Cancer Research and Treatment	2022
35378642	Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.	Breast Cancer Res Treat	2022
36215674	Development of an Electronic Health Record Registry to Facilitate Collection of Commission on Cancer Metrics for Patients Undergoing Surgery for Breast Cancer.	JCO clinical cancer informatics	2022
35876790	Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening.	Journal of the National Cancer Institute	2022
35810227	ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes.	Annals of Surgical Oncology	2022
35810224	Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer.	Annals of Surgical Oncology	2022
35688521	Regional Nodal Management After Preoperative Systemic Therapy.	Seminars in Radiation Oncology	2022
36001314	Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer.	JAMA network open	2022
35488092	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.	Breast Cancer Research and Treatment	2022
35366506	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.	Breast	2022
35737367	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.	JAMA Oncol	2022
35675571	Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.	J Clin Oncol	2022
35861759	ASO Visual Abstract: The Presence of Non-classic LCIS is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.	Annals of Surgical Oncology	2022
35675045	Surgical Decision-making in Early-Stage Breast Cancer-Trends and Opportunities.	JAMA Surgery	2022
35353260	Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer.	Annals of Surgical Oncology	2022
36116830	HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.	Eur J Cancer	2022
35538105	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.	NPJ Breast Cancer	2022